Quantum Biopharma (QNTM) Convertible Debt (2024 - 2026)

Quantum Biopharma's Convertible Debt history runs 3 years deep, the most recent figure standing at $485517.0 for Q1 2026.

• In Q1 2026, Convertible Debt rose 209.4% year-over-year to $485517.0; the TTM figure through Mar 2026 stood at $485517.0 (up 209.4% YoY), while the FY2025 annual figure was $472497.0, up 210.62% from the prior year.
• Convertible Debt came in at $485517.0 for Q1 2026 at Quantum Biopharma, up from $472497.0 in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $485517.0 in Q1 2026 to a low of $152113.0 in Q4 2024.
• A 3-year average of $310186.2 and a median of $297035.0 in 2025 frame the typical range for Convertible Debt.
• Across the five-year window, Convertible Debt surged 210.62% in 2025 and soared 209.4% in 2026, its largest moves.
• Quantum Biopharma's Convertible Debt stood at $152113.0 in 2024, then soared by 210.62% to $472497.0 in 2025, then grew by 2.76% to $485517.0 in 2026.
• According to Business Quant data, Convertible Debt over the past three periods registered $485517.0, $472497.0, and $429995.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison